135 related articles for article (PubMed ID: 10063994)
1. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent--a pilot study in the setting of coronary angioplasty.
Vuillemenot A; Schiele F; Meneveau N; Claudel S; Donat F; Fontecave S; Cariou R; Samama MM; Bassand JP
Thromb Haemost; 1999 Feb; 81(2):214-20. PubMed ID: 10063994
[TBL] [Abstract][Full Text] [Related]
2. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR
Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156
[TBL] [Abstract][Full Text] [Related]
3. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
[TBL] [Abstract][Full Text] [Related]
4. Intracoronary dipyridamole reduces the incidence of abrupt vessel closure following PTCA: a prospective randomised trial.
Heintzen MP; Heidland UE; Klimek WJ; Leschke M; Kelm M; Schwartzkopff B; Vester EG; Michel CJ; Strauer BE
Heart; 2000 May; 83(5):551-6. PubMed ID: 10768906
[TBL] [Abstract][Full Text] [Related]
5. [Intracoronary dipyridamole reduces the incidence of acute coronary vessel occlusion in percutaneous transluminal coronary angioplasty--a prospective randomized study].
Heintzen MP; Heidland UE; Klimek WJ; Michel CJ; Kelm M; Leschke M; Schwartzkopff B; Vester EG; Strauer BE
Z Kardiol; 1997 Dec; 86(12):961-7. PubMed ID: 9499493
[TBL] [Abstract][Full Text] [Related]
6. Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study.
Grip L; Blombäck M; Egberg N; Olsson A; Svane B; Velander M
Eur Heart J; 1997 Mar; 18(3):443-9. PubMed ID: 9076381
[TBL] [Abstract][Full Text] [Related]
7. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study.
Coussement PK; Bassand JP; Convens C; Vrolix M; Boland J; Grollier G; Michels R; Vahanian A; Vanderheyden M; Rupprecht HJ; Van de Werf F;
Eur Heart J; 2001 Sep; 22(18):1716-24. PubMed ID: 11511121
[TBL] [Abstract][Full Text] [Related]
8. The antithrombotic efficacy of the GP IIb/IIIa antagonist SR121787 is potentiated by antithrombin-dependent factor Xa inhibition without an increase in the bleeding risk in the rabbit.
Bernat A; Savi P; Lale A; Hoffmann P; Herbert JM
J Cardiovasc Pharmacol; 1999 Apr; 33(4):573-9. PubMed ID: 10218727
[TBL] [Abstract][Full Text] [Related]
9. Prevention and management of thrombotic complications during coronary interventions. Combination therapy with antithrombins, antiplatelets, and/or thrombolytics: risks and benefits.
Neuhaus KL; Zeymer U
Eur Heart J; 1995 Nov; 16 Suppl L():63-7. PubMed ID: 8869021
[TBL] [Abstract][Full Text] [Related]
10. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
[TBL] [Abstract][Full Text] [Related]
11. Comparison of a synthetic antithrombin III-binding pentasaccharide and standard heparin as an adjunct to coronary thrombolysis.
Pislaru SV; Pislaru C; Zhu X; Arnout J; Stassen T; Vanhove P; Herbert JM; Meuleman DG; Van de Werf F
Thromb Haemost; 1998 Jun; 79(6):1130-5. PubMed ID: 9657437
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive intracoronary infusion of antithrombin III during percutaneous transluminal coronary angioplasty. Results of a prospective, randomized trial.
Schächinger V; Allert M; Kasper W; Just H; Vach W; Zeiher AM
Circulation; 1994 Nov; 90(5):2258-66. PubMed ID: 7955182
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic treatment (argatroban vs. heparin) in coronary angioplasty in angina pectoris: effects on inflammatory, hemostatic, and endothelium-derived parameters.
Suzuki S; Matsuo T; Kobayashi H; Matsuo M; Shimamo C; Koide M; Sakamoto S
Thromb Res; 2000 May; 98(4):269-79. PubMed ID: 10822073
[TBL] [Abstract][Full Text] [Related]
14. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
[TBL] [Abstract][Full Text] [Related]
15. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
Ferguson JJ; Wilson JM; Diez J
Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
[TBL] [Abstract][Full Text] [Related]
16. Activated clotting time differential is a superior method of monitoring anticoagulation following coronary angioplasty.
Pitney MR; Kelly SA; Allan RM; Giles RW; McCredie M; Walsh WF
Cathet Cardiovasc Diagn; 1996 Feb; 37(2):145-50. PubMed ID: 8808069
[TBL] [Abstract][Full Text] [Related]
17. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures.
Gregorini L; Marco J; Fajadet J; Bernies M; Cassagneau B; Brunel P; Bossi IM; Mannucci PM
J Am Coll Cardiol; 1997 Jan; 29(1):13-20. PubMed ID: 8996289
[TBL] [Abstract][Full Text] [Related]
18. Role of thrombolysis and thrombin in patients with acute coronary occlusion during percutaneous transluminal coronary angioplasty.
Gulba DC; Daniel WG; Simon R; Jost S; Barthels M; Amende I; Rafflenbeul W; Lichtlen PR
J Am Coll Cardiol; 1990 Sep; 16(3):563-8. PubMed ID: 2117619
[TBL] [Abstract][Full Text] [Related]
19. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
[TBL] [Abstract][Full Text] [Related]
20. Systemic and translesional activation of coagulation, fibrinolytic, and inhibitory systems in candidates for coronary angioplasty: basal state and effect of successful dilation.
Lehmann KG; Gonzales E; Tri BD; Vaziri ND
Am Heart J; 1999 Feb; 137(2):274-83. PubMed ID: 9924161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
